The stock of Axsome Therapeutics Inc (AXSM) has seen a -15.94% decrease in the past week, with a -23.46% drop in the past month, and a -15.13% decrease in the past quarter. The volatility ratio for the week is 4.37%, and the volatility levels for the past 30 days are at 3.94% for AXSM. The simple moving average for the past 20 days is -17.88% for AXSM’s stock, with a -9.32% simple moving average for the past 200 days.
Is It Worth Investing in Axsome Therapeutics Inc (NASDAQ: AXSM) Right Now?
The stock has a 36-month beta value of 1.03. Opinions on the stock are mixed, with 12 analysts rating it as a “buy,” 5 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AXSM is 39.61M, and at present, short sellers hold a 16.45% of that float. On December 30, 2024, the average trading volume of AXSM was 502.06K shares.
AXSM) stock’s latest price update
The stock of Axsome Therapeutics Inc (NASDAQ: AXSM) has decreased by -12.03 when compared to last closing price of 86.70.Despite this, the company has seen a loss of -15.94% in its stock price over the last five trading days. benzinga.com reported 2024-12-30 that U.S. stock futures were lower this morning, with the Dow futures falling more than 50 points on Monday.
Analysts’ Opinion of AXSM
Many brokerage firms have already submitted their reports for AXSM stocks, with Wells Fargo repeating the rating for AXSM by listing it as a “Overweight.” The predicted price for AXSM in the upcoming period, according to Wells Fargo is $140 based on the research report published on September 03, 2024 of the current year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see AXSM reach a price target of $106, previously predicting the price at $95. The rating they have provided for AXSM stocks is “Buy” according to the report published on August 06th, 2024.
Needham gave a rating of “Buy” to AXSM, setting the target price at $130 in the report published on July 22nd of the current year.
AXSM Trading at -18.03% from the 50-Day Moving Average
After a stumble in the market that brought AXSM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -27.36% of loss for the given period.
Volatility was left at 3.94%, however, over the last 30 days, the volatility rate increased by 4.37%, as shares sank -21.39% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.29% lower at present.
During the last 5 trading sessions, AXSM fell by -14.90%, which changed the moving average for the period of 200-days by +10.71% in comparison to the 20-day moving average, which settled at $92.93. In addition, Axsome Therapeutics Inc saw -4.17% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AXSM starting from Saad Mark E, who sale 11,016 shares at the price of $91.31 back on Sep 11 ’24. After this action, Saad Mark E now owns 10,002 shares of Axsome Therapeutics Inc, valued at $1,005,871 using the latest closing price.
Saad Mark E, the Director of Axsome Therapeutics Inc, proposed sale 11,016 shares at $91.31 during a trade that took place back on Sep 11 ’24, which means that Saad Mark E is holding shares at $1,005,843 based on the most recent closing price.
Stock Fundamentals for AXSM
Current profitability levels for the company are sitting at:
- -0.91 for the present operating margin
- 0.91 for the gross margin
The net margin for Axsome Therapeutics Inc stands at -0.92. The total capital return value is set at -0.84. Equity return is now at value -171.61, with -53.51 for asset returns.
Based on Axsome Therapeutics Inc (AXSM), the company’s capital structure generated 0.66 points at debt to capital in total, while cash flow to debt ratio is standing at -0.74. The debt to equity ratio resting at 1.94. The interest coverage ratio of the stock is -60.75.
Currently, EBITDA for the company is -224.99 million with net debt to EBITDA at 0.45. When we switch over and look at the enterprise to sales, we see a ratio of 10.67. The receivables turnover for the company is 2.73for trailing twelve months and the total asset turnover is 0.6. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.44.
Conclusion
To sum up, Axsome Therapeutics Inc (AXSM) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
